Silver Creek Pharmaceuticals

Focus: Silver Creek Pharmaceuticals is an early-stage biotech founded in 2024, focused on regenerative medicines for neurology, currently headquartered in South San Francisco with fewer than 50 employees. The company is in Series A stage with a single Phase 2 program targeting acute ischemic stroke.

Neurology

Profile data last refreshed 13h ago · AI intelligence enriched 1w ago

Funding Stage

SERIES A

Employees

1-50

Open Jobs

About Silver Creek Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Silver Creek Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Placebo

Acute Ischemic Stroke (AIS)

Phase 2

Clinical Trials (1)

NCT05585606Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

Phase 2

Help build intelligence for Silver Creek Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company (2024) with potential to shape company culture and early scientific direction in regenerative medicine.
Focus on high-unmet-need neurology indication (acute ischemic stroke) with a Phase 2 program, offering visibility into clinical validation within 2–3 years.
Pre-revenue biotech structure offers equity upside potential if Series A funding and clinical progress accelerate the company's valuation trajectory.

Watch Out For

Zero active job openings at time of data collection signals either fully staffed early stage or limited near-term hiring; career mobility within the company may be constrained.
Ultra-early stage (founded 2024, Series A, 1–50 employees) carries significant execution risk; financial runway and future funding are unconfirmed.
Single clinical program and no revenue, publications, or partnerships documented; limited track record to evaluate management capability or scientific rigor.

Generated by Claude from Silver Creek Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 1 clinical trial

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline